Literature DB >> 24649200

Primary squamous cell carcinoma of the esophagus initially presenting as a large retroperitoneal mass: A case diagnosed as cancer of unknown primary site.

Lanfang Yu1, Xiaoxiao Ge1, Sui Huang1, Yanli Wang2, Peng Shen1.   

Abstract

Retroperitoneal squamous cell carcinoma (SCC) of unknown origin is uncommon. It is extremely rare when the primary site detected in the esophagus after 18 months. A 59-year-old female patient with waist pain was initially diagnosed as retroperitoneal metastatic SCC of occult origin. Six cycles of chemotherapy with cisplatin, paclitaxel and 5-fluorouracil were administered and clinical complete response was observed. The primary site was detected in the esophagus after 18 months and the overall survival (OS) was 28 months. To the best of our knowledge, this is the first case of esophageal squamous cell carcinoma (ESCC) initially presenting as a metastatic site with long progression-free survival (PFS) and OS. In conclusion, the different biological characteristics and complete response to first-line chemotherapy likely contribute to relatively long PFS and OS.

Entities:  

Keywords:  cancer of unknown primary; chemotherapy; esophageal cancer; squamous cell carcinoma

Year:  2013        PMID: 24649200      PMCID: PMC3915688          DOI: 10.3892/mco.2013.79

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

2.  Long-term survivors of esophageal carcinoma with distant lymph node metastasis.

Authors:  Shinichi Okamura; Hitoshi Fujiwara; Atsushi Shiozaki; Shuhei Komatsu; Daisuke Ichikawa; Kazuma Okamoto; Yasutoshi Murayama; Hisashi Ikoma; Yoshiaki Kuriu; Masayoshi Nakanishi; Toshiya Ochiai; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

3.  Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.

Authors:  Hyun-Jeong Shim; Sang-Hee Cho; Jun-Eul Hwang; Woo-Kyun Bae; Sang-Yun Song; Sung-Bum Cho; Wan-Sik Lee; Young-Eun Joo; Kook-Joo Na; Ik-Joo Chung
Journal:  Am J Clin Oncol       Date:  2010-12       Impact factor: 2.339

4.  [A case of a patient with stage IVa esophageal cancer surviving over 4 years by combination chemotherapy with docetaxel,5 -FU and cisplatin, without operation].

Authors:  Yota Yamamoto; Mayumi Ikeda; Mika Takashima; Takuya Minato; Yoshihito Furukita; Hirokazu Takechi; Junichi Seike; Akira Tangoku
Journal:  Gan To Kagaku Ryoho       Date:  2011-08

Review 5.  Pathologic evaluation of unknown primary cancer.

Authors:  Karin A Oien
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

6.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

7.  A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.

Authors:  Weiguo Cao; Chun Xu; Guying Lou; Jinsong Jiang; Shunguang Zhao; Mei Geng; Wenqi Xi; Hao Li; Yening Jin
Journal:  Jpn J Clin Oncol       Date:  2009-06-09       Impact factor: 3.019

8.  Metastatic and histologic presentations in unknown primary cancer.

Authors:  J S Nystrom; J M Weiner; J Heffelfinger-Juttner; L E Irwin; J R Bateman; R M Wolf
Journal:  Semin Oncol       Date:  1977-03       Impact factor: 4.929

Review 9.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer.

Authors:  Michael J Overman; Syed M Kazmi; Jagriti Jhamb; E Lin; James C Yao; James L Abbruzzese; Linus Ho; Jaffer Ajani; Alexandria Phan
Journal:  Cancer       Date:  2010-03-15       Impact factor: 6.860

View more
  3 in total

1.  Pelvic squamous cell cancer in an HIV-infected man with a history of high-grade anal dysplasia.

Authors:  Ulrike K Buchwald
Journal:  Int J Colorectal Dis       Date:  2015-10-07       Impact factor: 2.571

2.  Psoralidin inhibits proliferation and enhances apoptosis of human esophageal carcinoma cells via NF-κB and PI3K/Akt signaling pathways.

Authors:  Zhiliang Jin; Wei Yan; Hui Jin; Changzheng Ge; Yanhua Xu
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

3.  Male pelvic squamous cell carcinoma of unknown primary origin.

Authors:  Lauren Chiec; Sadhna Verma; Ady Kendler; Nagla Abdel Karim
Journal:  Case Rep Oncol Med       Date:  2014-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.